Progressive Multiple Sclerosis: IMU-838 Study

We are testing a new medication, IMU-838, to see if it helps reduce brain atrophy in patients with progressive multiple sclerosis. This study compares its effects to a placebo to evaluate its safety and tolerability.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Imu-838
Vidofludimus Calcium

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Mnogoprofilna Bolnitsa Za Aktivno Lechenie Puls AD
Department of Neurology Diseases
Blagoevgrad, Bulgaria
Multi-profile Hospital for Active Treatment Heart and Brain EAD
Second Department of Neurology Diseases
Burgas, Bulgaria
Umbal - Prof. D-R Stoyan Kirkovich AD
Clinic of Neurology Diseases
Kardzhali, Bulgaria

Sponsor: Immunic AG
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.